Analyst Ratings For Futura Medical plc. (LON:FUM)
Today, N+1 Singer reiterated its Corporate rating on Futura Medical plc. (LON:FUM).
There are no ratings tracked in the last 12 months. on the stock.
The current consensus rating on Futura Medical plc. (LON:FUM) is N/A (Score: NaN) with a consensus target price of per share, a potential .
Some recent analyst ratings include
- 3/6/2017-N+1 Singer Reiterated Rating of Corporate.
About Futura Medical plc. (LON:FUM)
Futura Medical plc is a United Kingdom-based pharmaceutical company that develops products for consumer healthcare. The Company is engaged in the research and development of pharmaceutical drugs and medical devices and the commercial exploitation. It is also engaged in transdermal delivery and has developed a transdermal technology, DermaSys for the absorption of active molecules through the skin. It specializes in sexual health and pain relief, and has approximately five products in its development pipeline, which include CSD500, MED2002, TPR100, TIB200 and SPR300. Its CSD500 product incorporates an erectogenic gel (known as Zanifil gel) to help men maintain a firmer erection during intercourse whilst wearing a condom. Its MED2002 is a gel applied directly to the penis for the treatment of male erectile dysfunction (ED). The Company’s TPR100 is a gel to provide pain relief. Its SPR300 is a gel, which combines methyl salicylate and menthol with the DermaSys delivery system.
Recent Trading Activity for Futura Medical plc. (LON:FUM)
Shares of Futura Medical plc. closed the previous trading session at 59.15 up +9.15 18.30% with 0 shares trading hands.
